Exploring the association of natriuretic peptides with QTc interval in hemodialysis patients

Yoshihiro Matsumoto1, Yasuo Mori2, Shinji Kageyama3

  • 1Nephrology and Dialysis, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.

Renal Failure
|February 18, 2025
PubMed

Insights

In hemodialysis patients, N-terminal proBNP (NT-proBNP) strongly predicts prolonged QTc intervals, more so than other natriuretic peptides. Monitoring NT-proBNP, potassium, and calcium may help reduce cardiovascular events.

Area of Science:

  • Nephrology
  • Cardiology
  • Biochemistry

Background:

  • Cardiovascular disease, especially sudden cardiac death, is a leading cause of mortality in hemodialysis patients.
  • Prolonged QT interval and elevated natriuretic peptides are known predictors of sudden cardiac death.
  • The relationship between natriuretic peptides and QT interval in hemodialysis patients requires further investigation.

Purpose of the Study:

  • To explore the association between the QTc interval and various natriuretic peptides (ANP, BNP, NT-proBNP) in hemodialysis patients.
  • To identify predictors of a prolonged QTc interval in this patient population.

Main Methods:

  • A cross-sectional study of 207 hemodialysis patients with specific ECG criteria (sinus rhythm, no extrasystoles).
  • ECG and blood samples for ANP, BNP, and NT-proBNP were collected before dialysis.
  • The heart rate-corrected QT (QTc) interval was calculated using Bazett's formula.

Main Results:

  • All measured natriuretic peptides (ANP, BNP, NT-proBNP) were significantly associated with the QTc interval in univariate analyses.
  • Multiple regression analysis indicated that NT-proBNP was the strongest predictor of the QTc interval.
  • Independent predictors of prolonged QTc included lower corrected calcium (cCa), lower potassium (K), and higher log NT-proBNP levels.

Conclusions:

  • NT-proBNP demonstrates a stronger association with the QTc interval compared to BNP or ANP in hemodialysis patients.
  • Clinical management incorporating QTc interval and NT-proBNP levels may help reduce cardiovascular events.
  • Attention to low potassium and corrected calcium levels is advisable for managing the QTc interval in hemodialysis patients.
Abstract

Related Concept Videos

Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
334
Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
439
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
371
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
522
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...
105
Antihypertensive Drugs: Action of Diuretics01:16

Antihypertensive Drugs: Action of Diuretics

Diuretics are antihypertensive drugs used to treat hypertension resulting from sodium and water retention. Sodium, vital for fluid balance and nerve or muscle function, is regulated by the kidneys through millions of nephrons. Blood enters nephrons via afferent arterioles, which branch into capillaries called glomeruli. These filter blood plasma, allowing water and solutes, like sodium ions, to pass through capillary walls into Bowman's capsule. The filtrate then flows through various...
613